Thymic Carcinoma
42
8
14
13
Key Insights
Highlights
Success Rate
65% trial completion
Published Results
11 trials with published results (26%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
16.7%
7 terminated out of 42 trials
65.0%
-21.5% vs benchmark
2%
1 trials in Phase 3/4
85%
11 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (42)
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Molecular Analysis of Thoracic Malignancies
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Survival Nomogram for Patients With Thymic Carcinoma
Molecular Analysis and Treatment Options of Thymic Malignancies
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)